S&P 500   4,242.46 (+0.84%)
DOW   33,537.26 (+0.60%)
QQQ   327.88 (+1.17%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.46 (+0.84%)
DOW   33,537.26 (+0.60%)
QQQ   327.88 (+1.17%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.46 (+0.84%)
DOW   33,537.26 (+0.60%)
QQQ   327.88 (+1.17%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.46 (+0.84%)
DOW   33,537.26 (+0.60%)
QQQ   327.88 (+1.17%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
NYSE:GMED

Globus Medical - GMED Stock Forecast, Price & News

$66.29
+0.98 (+1.50%)
(As of 08/12/2022 11:39 AM ET)
Add
Compare
Today's Range
$64.87
$66.39
50-Day Range
$53.08
$65.31
52-Week Range
$52.60
$84.23
Volume
6,031 shs
Average Volume
699,761 shs
Market Capitalization
$6.60 billion
P/E Ratio
44.49
Dividend Yield
N/A
Price Target
$77.36

Globus Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
18.8% Upside
$77.36 Price Target
Short Interest
Bearish
6.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.22mentions of Globus Medical in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.29%
From $2.10 to $2.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

436th out of 1,112 stocks

Surgical & Medical Instruments Industry

47th out of 113 stocks

GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical Stock Down 0.0 %

NYSE:GMED traded down $0.03 during trading on Thursday, hitting $65.13. The stock had a trading volume of 23,696 shares, compared to its average volume of 678,841. The company has a market capitalization of $6.63 billion, a PE ratio of 43.73, a PEG ratio of 3.05 and a beta of 1.13. Globus Medical has a twelve month low of $52.60 and a twelve month high of $84.23. The firm has a 50 day moving average price of $58.45 and a 200 day moving average price of $65.37.

Globus Medical (NYSE:GMED - Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The medical device company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). The business had revenue of $230.55 million during the quarter, compared to analyst estimates of $232.88 million. Globus Medical had a return on equity of 11.81% and a net margin of 15.91%. The business's revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 EPS. On average, sell-side analysts anticipate that Globus Medical will post 2.1 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on GMED shares. BTIG Research decreased their price objective on shares of Globus Medical to $71.00 in a research report on Tuesday. Truist Financial dropped their price objective on Globus Medical from $76.00 to $71.00 and set a "buy" rating on the stock in a report on Wednesday, July 20th. Wells Fargo & Company reduced their target price on Globus Medical from $80.00 to $70.00 in a research note on Wednesday, May 11th. Canaccord Genuity Group decreased their price objective on shares of Globus Medical from $80.00 to $75.00 in a report on Wednesday, May 11th. Finally, Piper Sandler cut their target price on shares of Globus Medical from $80.00 to $75.00 and set an "overweight" rating for the company in a research note on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Globus Medical has an average rating of "Moderate Buy" and a consensus price target of $77.36.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Analyst Ratings for Globus Medical
Globus Medical (GMED) Q2 2022 Earnings Call Transcript
Globus Medical Reports Second Quarter 2022 Results
A Breakout Stock Is On The Way
First movers have always done well. Could this stock be next?
What 5 Analyst Ratings Have To Say About Globus Medical
Globus Medical Inc Class A - Stock Quote GMED
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
11/04/2021
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.36
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+16.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$149.19 million
Pretax Margin
19.89%

Debt

Sales & Book Value

Annual Sales
$958.10 million
Cash Flow
$2.85 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
76,914,000
Market Cap
$6.60 billion
Optionable
Optionable
Beta
1.13

Key Executives














GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2022?

9 brokerages have issued twelve-month target prices for Globus Medical's stock. Their GMED share price forecasts range from $62.00 to $100.00. On average, they expect the company's stock price to reach $77.36 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2022?

Globus Medical's stock was trading at $72.20 at the beginning of the year. Since then, GMED shares have decreased by 9.5% and is now trading at $65.31.
View the best growth stocks for 2022 here
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its quarterly earnings data on Thursday, November, 4th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.45 by $0.05. The medical device company had revenue of $229.72 million for the quarter, compared to analysts' expectations of $228.28 million. Globus Medical had a net margin of 15.91% and a trailing twelve-month return on equity of 11.81%. Globus Medical's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 earnings per share.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of $2.10-$2.10 for the period, compared to the consensus estimate of $2.09. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (1.70%), Geneva Capital Management LLC (1.33%), Eagle Asset Management Inc. (0.92%), Van Berkom & Associates Inc. (0.87%), Paradigm Capital Management Inc. NY (0.68%) and Boston Trust Walden Corp (0.63%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $65.31.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $6.65 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Globus Medical have?

The company employs 2,400 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.